Targeting the Biology of Aging
We neutralize Galectin-3 to resolve chronic inflammaging. While we build the foundation for global healthspan extension, we are providing immediate options for patients through our Expanded Access Program.
If it works in the brain, it works everywhere.
Neurodegeneration is the "ultimate test" for any healthspan platform. The blood-brain barrier and microglial complexity represent the most difficult environments to resolve chronic inflammation.
Demonstrating Gal-3 inhibition in this highly restrictive environment effectively de-risks the broader potency of our systemic antibody.
TB006 Expanded Access Program
TThe FDA-authorized Expanded Access Program (EAP) for investigational TB006 permits eligible patients with dementia, including Alzheimer’s disease to request access to the product outside of clinical trials. The program is intended for patients with serious or life-threatening conditions who are unable to participate in clinical studies and who lack satisfactory alternative treatment options.
TB006 is an investigational drug, and its safety and effectiveness have not been established. The Expanded Access Program operates in accordance with FDA regulations while clinical development of TB006 continues.
Completion of Phase 1b/2a Clinical Trial for Alzheimer's Disease
Topline data from a one-month TB006 treatment regimen shows improvements in Clinical Dementia Rating-Sum of Boxes (CDR-SB) in patients, indicating the potential of slowing or reducing clinical decline. Key secondary endpoints were consistent with the primary findings.
Latest News
April, 2025
The FDA has renewed the Expanded Access Program (NCT05959239) for TB006 in treating dementia and Alzheimer's disease. This renewal allows existing patients to continue receiving TB006 outside of traditional clinical trials and offers hope for patients seeking alternative treatment options.
November, 2025
In a recent abstract published in Neuro-Oncology, TrueBinding partnered with UCSF to present new findings under a supplement of the journal’s 2025 volume.
Vo A. H., Yang E., Raleigh D. R., Lan N., Savic R., Butowski N. “TIP-02. Evaluation of TB006, a Galectin-3 antibody, for the treatment of Glioblastoma.” Neuro-Oncology, vol. 27, supplement 5, Nov. 2025, p. v420.
Nov 18, 2024
TrueBinding has cleared an FDA IND application for TB006 for potential disease modification of Parkinson’s Disease. A multi-center, placebo-controlled, Phase 2A trial (NCT06773962) of TB006 in the U.S. will be evaluating the safety and efficacy of this treatment in patients with early to mild Parkinson’s Disease.